Metabolic Brain Disease

, Volume 33, Issue 3, pp 829–835 | Cite as

Late-onset cobalamin C deficiency Chinese sibling patients with neuropsychiatric presentations

  • Sheng-jun Wang
  • Chuan-zhu Yan
  • Yi-ming Liu
  • Yu-ying Zhao
Original Article

Abstract

The Cobalamin C deficiency (cblC), characterized with elevated methylmalonic acidemia and homocystinuria in plasma, is an inborn error of cobalamin metabolism. The late-onset cblC siblings patients were rarely reported. In this study, we analyzed the clinical presentations and treatment outcomes of late-onset cblC in Chinese sibling patients with neuropsychiatric presentations. The clinical data of four pairs of Chinese patients were retrospectively analyzed. Serum homocysteine, urine organic acids measurements, neuroimaging exams and gene analysis were carried out in all patents. Patients were reevaluated after treatments with cobalamin, folate, betaine, L-carnitine and compound vitamin B. The mean age at disease onset was 13.7 (range 2–19) years. The neuropsychiatric disturbances including cognitive decline (3/8), psychiatric disturbances (4/8), gait instability (2/8), lower extremity weakness and numbness (3/8) and thromboembolic events (1/8). Two patients suffered nephropathy. The mean serum homocysteine when patients were diagnosed was 109.4 (range 69.5–138) μM/L. The abnormal radioimaging included scoliosis by X-ray (5/6), cerebral atrophy (4/6) and spinal cord atrophy (3/6) by MRI scan. Three pairs of siblings showed heterozygous mutations of MMACHC gene including c.482G > A (4/6), c.354G > C (2/6), c.570insT (2/6), c.445_446del (2/6) and c.656_4658del (2/6). The other two siblings showed homozygous mutation with c.452A > G in MMACHC gene. After treatments, the psychiatric symptoms were obviously relieved in all the patients. In Chinese siblings with late-onset cblC, the main clinic manifestation and abnormal radioimaging were cognitive decline and cerebral atrophy respectively. The most common gene mutation was c.482G > A of MMACHC gene. The patients responded well to the treatments.

Keywords

Cobalamin Methylmalonic acidemia Homocystinuria Late onset Sibling 

Notes

Acknowledgements

This work is supported by grants from Natural Science Foundation of Shandong Province, China (No.ZR2017MH082) and Innovative Research Project of Resident Standardization Training of Qilu Hospital, Shandong University (No.ZPZX2017B10).

Author contributions

Dr. Sheng-jun Wang was responsible for the analysis of data and drafting of the manuscript.

Chuan-zhu Yan was responsible for the interpretation of data and revision of the manuscript.

Yi-ming Liu was responsible for interpretation of clinical data and revision of manuscript.

Dr. Yu-ying Zhao was responsible for critical revision and final approval of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors report no disclosures relevant to the manuscript. There are no conflicts of interest in this manuscript.

References

  1. Augoustides-Savvopoulou P, Mylonas I, Sewell AC, Rosenblatt DS (1999) Reversible dementia in an adolescent with cblC disease: Clinical heterogeneity within the same family. J Inherit Metab Dis 22:756–758CrossRefPubMedGoogle Scholar
  2. Boxer A, Kramer J, Johnston K, Goldman J, Finley R, Miller B (2005) Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment. Neurology 64:1431–1414CrossRefPubMedGoogle Scholar
  3. Carrillo-Carrasco N, Chandler RJ, Venditti CP (2012) Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis 35:91–102CrossRefPubMedGoogle Scholar
  4. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, Burlina AB, Cerone R, Garcia P, Gökçay G, Grünewald S, Häberle J, Jaeken J, Ketteridge D, Lindner M, Mandel H, Martinelli D, Martins EG, Schwab KO, Gruenert SC, Schwahn BC, Sztriha L, Tomaske M, Trefz F, Vilarinho L, Rosenblatt DS, Fowler B, Dionisi-Vici C (2014) Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis 37:831–840CrossRefPubMedGoogle Scholar
  5. Gold R, Bogdahn U, Kappos L, Toyka KV, Baumgartner ER, Fowler B, Wendel U (1996) Hereditary defect of cobalamin metabolism (homocystinuria andmethylmalonic aciduria) of juvenile onset. J Neurol Neurosurg Psychiatry 60:107–108CrossRefPubMedPubMedCentralGoogle Scholar
  6. Goodman SI, Moe PE, Hammond KB, Mudd SH, Uhlendorf BW (1970) Homocystinuria with methylmalonic aciduria: two cases in a sibship. Biochem Med 4:500–515CrossRefPubMedGoogle Scholar
  7. Huemer M, Scholl-Bürgi S, Hadaya K, Kern I, Beer R, Seppi K, Fowler B, Baumgartner MR, Karall D (2014) Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis 9:161CrossRefPubMedPubMedCentralGoogle Scholar
  8. Kölker S, Sauer SW, Hoffmann GF, Müller I, Morath MA, Okun JG (2008) Pathogenesis of CNS involvement in disorders of amino acid and organic acid metabolism. J Inherit Metab Dis 31:194–204CrossRefPubMedGoogle Scholar
  9. Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, Morel CF, Fujiwara TM, Moras E, Hosack AR, Dunbar GV, Antonicka H, Forgetta V, Dobson CM, Leclerc D, Gravel RA, Shoubridge EA, Coulton JW, Lepage P, Rommens JM, Morgan K, Rosenblatt DS (2006) Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet 38:93–100CrossRefPubMedGoogle Scholar
  10. Liu MY, Yang YL, Chang YC, Chiang S, Lin SP, Han LS, Qi Y, Hsiao KJ, Liu TT (2010) Mutation spectrum of MMACHC in Chinese patients with combined methylmalonic aciduria and homocystinuria. J Hum Genet 55:621–626CrossRefPubMedGoogle Scholar
  11. Liu YR, Ji YF, Wang YL, Zhang BA, Fang GY, Wang JT, Sun GF, Lu H (2015) Clinical analysis of late-onset methylmalonic acidaemia and homocystinuria, cblC type with a neuropsychiatric presentation. J Neurol Neurosurg Psychiatry 86:472–475CrossRefPubMedGoogle Scholar
  12. Martina H, Daria D, Bernd S, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia-Cazorla A, la Marca G, Pasquini E, Vilarinho L, Weisfeld-Adams JD, Kožich V, Blom H, Baumgartner MR, Dionisi-Vici C (2017) Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis 40:21–48CrossRefGoogle Scholar
  13. Martinelli D, Deodato F, Dionisi-Vici C (2011) Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis 34:127–135CrossRefPubMedGoogle Scholar
  14. Powers J, Rosenblatt D, Schmidt R, Cross AH, Black JT, Moser AB, Moser HW, Morgan DJ (2001) Neurological and neuropathologic heterogeneity in two brothers with cobalamin C deficiency. Ann Neurol 49:396–400CrossRefPubMedGoogle Scholar
  15. Wang F, Han L, Yang Y, Gu X, Ye J, Qiu W (2010) Clinical, biochemical, and molecular analysis of combinedmethylmalonic acidemia and hyperhomocysteinemia (cblC type) in China. J Inherit Metab Dis 33(suppl 3):S435–S442CrossRefPubMedGoogle Scholar
  16. Wang X, Sun W, Yang Y, Jia J, Li C (2012) A clinical and gene analysis of late-onset combined methylmalonicaciduria and homocystinuria, cblC type, in China. J Neurol Sci 318:155–159CrossRefPubMedGoogle Scholar
  17. Wu L, An H, Liu J, Li JY, Han Y, Zhou AH, Wang F, Jia JP (2017) Manic-depressive Psychosis as the Initial Symptom in Adult Siblings with Late-onset Combined Methylmalonic Aciduria and Homocystinemia, Cobalamin C Type. Chin Med J 130:492–494CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sheng-jun Wang
    • 1
  • Chuan-zhu Yan
    • 1
  • Yi-ming Liu
    • 1
  • Yu-ying Zhao
    • 1
  1. 1.Department of Neurology, Qilu HospitalShandong UniversityJi’nanPeople’s Republic of China

Personalised recommendations